Linc00941 Is a Novel Transforming Growth Factor β Target That Primes Papillary Thyroid Cancer Metastatic Behavior by Regulating the Expression of Cadherin 6

Thyroid ◽  
2020 ◽  
Author(s):  
Mila Gugnoni ◽  
Veronica Manicardi ◽  
Federica Torricelli ◽  
Elisabetta Sauta ◽  
Riccardo Bellazzi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Growth Factor ◽  
Papillary Thyroid Cancer ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Papillary Thyroid ◽  
Metastatic Behavior

scholarly journals Mediator complex subunit 16 is down-regulated in papillary thyroid cancer, leading to increased transforming growth factor-β signaling and radioiodine resistance

2020 ◽  
Vol 295 (31) ◽  
pp. 10726-10740
Author(s):  
Hongwei Gao ◽  
Peirong Bai ◽  
Lin Xiao ◽  
Mengjia Shen ◽  
Qiuxiao Yu ◽  
...  
Keyword(s):  
Cell Migration ◽  
Thyroid Cancer ◽  
Growth Factor ◽  
Sodium Iodide ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β ◽  
Mediator Complex ◽  
Papillary Thyroid ◽  
Sodium Iodide Symporter

Mediator complex subunit 16 (MED16) is a component of the mediator complex and functions as a coactivator in transcriptional events at almost all RNA polymerase II–dependent genes. In this study, we report that the expression of MED16 is markedly decreased in papillary thyroid cancer (PTC) tumors compared with normal thyroid tissues. In vitro, MED16 overexpression in PTC cells significantly inhibited cell migration, enhanced sodium/iodide symporter expression and iodine uptake, and decreased resistance to radioactive 131I (RAI). Conversely, PTC cells in which MED16 had been further knocked down (MED16KD) exhibited enhanced cell migration, epithelial–mesenchymal transition, and RAI resistance, accompanied by decreased sodium/iodide symporter levels. Moreover, cell signaling through transforming growth factor β (TGF-β) was highly activated after the MED16 knockdown. Similar results were obtained in MED12KD PTC cells, and a co-immunoprecipitation experiment verified interactions between MED16 and MED12 and between MED16 and TGF-βR2. Of note, the application of LY2157299, a potent inhibitor of TGF-β signaling, significantly attenuated MED16KD-induced RAI resistance both in vitro and in vivo. In conclusion, our findings indicate that MED16 reduction in PTC contributes to tumor progression and RAI resistance via the activation of the TGF-β pathway.

Papillary Thyroid Cancer in Children and Adolescents Does Not Differ in Growth Pattern and Metastatic Behavior

2010 ◽  
Vol 157 (4) ◽  
pp. 648-652 ◽  
Author(s):  
Andreas Machens ◽  
Kerstin Lorenz ◽  
Phuong Nguyen Thanh ◽  
Michael Brauckhoff ◽  
Henning Dralle
Keyword(s):  
Thyroid Cancer ◽  
Children And Adolescents ◽  
Papillary Thyroid Cancer ◽  
Growth Pattern ◽  
Papillary Thyroid ◽  
Metastatic Behavior ◽  
Cancer In Children

scholarly journals INSULIN-LIKE GROWTH FACTORS IN THE SERUM OF PATIENTS WITH PAPILLARY THYROID CANCER

2021 ◽  
Vol 74 (8) ◽  
pp. 1925-1930
Author(s):  
Nataliia S. Pidchenko ◽  
Mykola V. Krasnoselskyi ◽  
Nataliia A. Mitriaieva ◽  
Lidiya V. Grebenik ◽  
Olha M. Astapieva ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Growth Factors ◽  
Growth Factor ◽  
Blood Serum ◽  
Papillary Thyroid Cancer ◽  
The Body ◽  
Control Group ◽  
Insulin Like Growth Factor ◽  
Papillary Thyroid ◽  
Insulin Like Growth Factors

The aim is to study the level of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2) in the blood serum of patients with papillary thyroid cancer, depending on the main clinical and morphological features of the disease. Materials and methods: The material was the information about 60 patients with papillary thyroid cancer (group 1). In group 2 there were 10 patients without oncopathology. All patients underwent clinical examination after total thyroidectomy before special treatment (radioiodine therapy): ultrasound diagnosis of the neck, confirmed diagnosis of papillary thyroid cancer by morphological examination of operative material. All patients underwent anthropometric studies (height, weight), on the basis of which the body mass index (BMI) was calculated. The study program also included determination of the level of thyroid-stimulating hormone of the pituitary gland (TSH), thyroglobulin (TG), antibodies to thyroglobulin (AB-TG). It was also determined the serum glucose level. In order to assess insulin resistance, the HOMA-IR index was calculated. All patients were tested for serum IGF-1 and IGF-2. Results: In the blood serum of patients with papillary thyroid cancer in 63% of patients the level of IGF-1 and in 85% – IGF-2 was probably higher than in the control group. There is a relationship between the level of IGF-1, IGF-2 and elevated level of proliferating factor – insulin in the serum of patients with papillary thyroid cancer. This may indicate an aggressive potential of the disease (i.e. clinical data on the prevalence of papillary thyroid cancer coincide with laboratory data). There was found a relationship between the expression of IGF-1, IGF-2 and insulin: at elevated levels of insulin> 24.9 μIU/ml, IGF-1 increases 4.2 times, and IGF-2 – 2.5 times. Evaluation of the relationship between the level of IGF-1 and IGF-2 and cervical lymph node involvement shows that in the absence of lesion (N0) there is an increase in these indicators by 2.2 and 1.8 times, respectively. Conclusions: The signaling system of insulin-like growth factors (IGF-1 and IGF-2) plays an important role in the occurrence and progression of malignant tumors. It is especially true for papillary thyroid cancer, so its components can be considered as potential diagnostic and prognostic markers of the disease and targets for anticancer therapy.

Sign in / Sign up

Export Citation Format

Share Document